Browse the evidence

The type of protein consumed can affect feeding- and exercise-mediated rates of MPS.

Choosing the right type of protein may enhance muscle recovery and growth post-exercise.

Quality of life outcomes generally showed improvements with incretin-based therapies (IBTs).

Clinicians can expect improvements in quality of life for patients using IBTs.

USB were a better replacement than ASB for altering taste preference.

Practitioners should consider promoting USB over ASB for better adherence to low-sugar diets.

Higher ultraprocessed grain intake is associated with increased risk of developing inflammatory bowel disease (IBD), with participants consuming ≥19 g/d having a hazard ratio (HR) of 1.86 compared to those consuming <9 g/d.

Practitioners should advise minimizing ultraprocessed grain consumption to reduce IBD risk.

Fresh bread and rice consumption are associated with lower IBD risk.

Encouraging the consumption of fresh bread and rice may be beneficial for gut health.

Participants with greater ultraprocessed food intake (≥5 servings per day) are linked to a higher risk of developing IBD, with a hazard ratio of 3.95 compared to those consuming <1 serving per day.

Reducing ultraprocessed food intake may lower the risk of IBD.

Understanding patient concerns about the risks of obesity treatment is essential to addressing obesity treatment inertia.

Addressing these concerns may help improve treatment adherence and outcomes.

Baseline body fat percentage was significantly associated with weight gains (r = 0.57) and fat mass gains (r = 0.59) during an 8-week high-fat overfeeding intervention.

Practitioners should consider baseline body fat percentage when assessing weight gain responses to overfeeding.

Body fat percentage was inversely associated with the energy cost of weight (r = -0.38) and fat mass (r = -0.40) gains.

Higher body fat percentage may indicate lower energy efficiency in gaining weight.

Semaglutide improved glycemic control, with HbA1c decreasing by 0.4 ± 0.6%.

Semaglutide may be a beneficial treatment for improving glycemic control in patients with type 1 diabetes.

1 kg/m² lower BMI via the GIP/GIPR score is associated with 29% lower risk of major adverse cardiovascular events (MACE).

Targeting GIP receptor pathways may significantly reduce cardiovascular event risk.

1 kg/m² lower BMI via the GIP/GIPR score is associated with 43% lower risk of heart failure.

Targeting GIP receptor pathways may significantly reduce heart failure risk.

Genetic proxies for body weight reduction via GIP receptor targeting reduces the risk of MACE and heart failure, mediated partly through lower BMI and partly through lower HbA1c.

Understanding GIP receptor pathways can inform strategies for reducing cardiovascular risks.

Semaglutide users experienced modest weight reductions ranging from 0.42 kg to 1.16 kg.

Practitioners may consider Semaglutide for modest weight loss in type 2 diabetes management.

The study identified key themes for safe practices in BMT, including psychological health, sleep apnea, cardiovascular disease, liver health, and dietetic assessment.

Practitioners should consider these health factors when evaluating patients for BMT.

Lifestyle intervention alone is typically associated with approximately 2%-5% weight loss at 1 year of follow-up.

Practitioners should set realistic weight loss expectations for patients relying solely on lifestyle changes.

Bariatric surgery has the greatest degree of expected weight loss, at around 20%-30% at 1 year.

Bariatric surgery may be the most effective option for patients needing significant weight loss.

Menopause is associated with weight gain and a predisposition to obesity in women.

Practitioners should be aware of the increased risk of weight gain in menopausal women.

Women begin to lose lean mass during menopause, leading to an increase in fat mass.

Practitioners should monitor body composition changes in menopausal women.

Targeted antiobesity medications (AOM) have demonstrated significant weight loss and improved quality of life in patients with specific genetic obesity disorders.

Practitioners should consider targeted AOMs for patients with genetic obesity disorders to improve weight management and quality of life.

Nontargeted AOMs can achieve similar benefits in patients with specific genetic obesity disorders compared to common multifactorial obesity.

Practitioners may consider nontargeted AOMs as an alternative for managing obesity in patients with genetic disorders.

GLP-1RA-induced weight loss would lead to a marked decrease in cancer cases over 10 years in adults.

Implementing GLP-1RA treatments could significantly reduce cancer incidence in obese populations.

If GLP-1RAs were made available for all people with obesity and 50% moved into a lower BMI category, there would be a simulated reduction in cumulative cancer cases of 21,443.

Wider access to GLP-1RAs could lead to significant reductions in cancer cases among obese individuals.

Significant reductions in diastolic BP (-1.5 mm Hg) and systolic BP (-1.1 mm Hg) were observed.

Semaglutide may help lower blood pressure in adults.